AstraZeneca’s Latest Study on Dato-DXd for NSCLC: Key Insights for Investors

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled ‘TROPION-Lung15’ to evaluate the efficacy and safety of Dato-DXd, with or without Osimertinib, compared to platinum-based doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on prior Osimertinib treatment. The study aims to improve progression-free survival (PFS) in this patient population.

The study tests two experimental interventions: Dato-DXd combined with Osimertinib and Dato-DXd monotherapy. Dato-DXd is administered intravenously, while Osimertinib is taken orally. The third intervention is the standard platinum-based doublet chemotherapy, involving drugs like Pemetrexed, Carboplatin, or Cisplatin.

This open-label, randomized study involves three parallel groups, with participants allocated randomly to receive one of the three treatments. The primary purpose is treatment-focused, with no masking involved, allowing for direct comparison of the interventions’ effectiveness.

The study began on October 4, 2024, with the last update submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates or results.

For investors, this study could significantly impact AstraZeneca’s stock performance, especially if the results show a marked improvement in treatment outcomes. The competitive landscape in the oncology sector, particularly for NSCLC, makes this study’s results highly anticipated, potentially influencing market dynamics and investor sentiment.

The study is currently ongoing, with further details available on the ClinicalTrials portal.